Skip to main content

Table 1 Metabolic changes during supply ischemia protocol

From: Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies

 

Baseline

Balloon occlusion 1 (BO1)

Balloon occlusion 2 (BO2)

 

p value*

 

p value*

 

p value*

GLP-1 (7–36) amide, pg/ml

 Control

2.9 ± 3.57

–

3.6 ± 4.13

–

2.9 ± 1.84

–

 GLP-1 only

2.8 ± 1.43

0.51

2.5 ± 2.04

0.49

87.5 ± 37.1

<0.001

 Glibenclamide only

1.9 ± 1.66

0.46

1.1 ± 0.77

0.11

1.3 ± 0.54

0.07

 GLP-1 glibenclamide

2.2 ± 0.59

0.57

2.3 ± 1.32

0.37

78.9 ± 31.1

<0.001

Insulin, pmol/L

 Control

79 ± 26

–

59 ± 29

–

58 ± 29

–

 GLP-1 only

77 ± 52

0.91

63 ± 85

0.82

95 ± 64

0.16

 Glibenclamide only

103 ± 93

0.51

292 ± 245

0.02

382 ± 297

0.02

 GLP-1 glibenclamide

90 ± 51

0.63

412 ± 244

<0.01

1133 ± 1089

0.03

Glucose, mmol/l

 Control

5.1 ± 0.3

–

5.3 ± 0.3

–

5.4 ± 0.4

–

 GLP-1 only

5.0 ± 0.3

0.83

5.0 ± 0.3

0.51

4.7 ± 0.3

0.20

 Glibenclamide only

5.3 ± 0.3

0.66

6.3 ± 0.4

0.06

6.8 ± 0.4

0.02

 GLP-1 glibenclamide

5.5 ± 0.3

0.44

5.9 ± 0.4

0.27

5.9 ± 0.7

0.45

Free fatty acids, μmol/L

 Control

371 ± 364

–

1399 ± 973

–

1050 ± 637

–

 GLP-1 only

473 ± 367

0.57

1213 ± 897

0.69

917 ± 516

0.64

 Glibenclamide only

358 ± 201

0.93

633 ± 434

0.06

439 ± 248

0.02

 GLP-1 glibenclamide

356 ± 183

0.91

846 ± 490

0.16

503 ± 307

0.04

Dextrose infusion, mg kg−1 min−1

 Glibenclamide only

–

–

1.69 ± 0.53

–

1.69 ± 0.53

–

 GLP-1 glibenclamide

–

–

2.25 ± 1.6

–

2.44 ± 1.59

–

  1. * p value compared with control group
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840